You've probably tried at least one PCOS supplement. Maybe it had Myo-Inositol. Maybe it claimed to "balance hormones." And maybe — like most women — you didn't see the results you were hoping for. Not because inositol doesn't work. The peer-reviewed evidence on that is actually quite strong. But because the ratio of inositol isomers is the variable that most supplement brands either get wrong or ignore entirely.
This article examines the clinical mechanism behind Myo-Inositol and D-Chiro-Inositol in polycystic ovary syndrome (PCOS), with particular focus on why the 40:1 Myo-Inositol to D-Chiro-Inositol ratio has emerged as the clinically studied standard — and what happens when that ratio is disrupted.
The Two Inositols: What They Are and Why Both Matter
Inositol is a carbocyclic polyol synthesised endogenously in the kidneys and liver, and obtained exogenously through dietary sources including fruits, legumes, and whole grains. Of its nine naturally occurring stereoisomers, two are physiologically significant in reproductive endocrinology: Myo-Inositol (MI) and D-Chiro-Inositol (DCI).
They are not interchangeable. Each has a distinct and non-overlapping function in cellular insulin signalling:
- Myo-Inositol acts as a second messenger for follicle-stimulating hormone (FSH) within the ovarian granulosa cells. It facilitates the conversion of androstenedione to oestrogen, promotes follicle maturation, and is required for normal oocyte quality. Deficiency of MI in ovarian follicular fluid is a documented feature of PCOS (Unfer et al., 2017).
- D-Chiro-Inositol acts as a mediator of insulin action at the systemic level, promoting glycogen synthesis and reducing androgen production in thecal cells. Its physiological role is primarily metabolic — normalising insulin-stimulated glucose uptake in peripheral tissues (Croze & Soulage, 2013).
In healthy ovarian tissue, MI and DCI exist in a ratio of approximately 100:1, reflecting the predominantly MI-dependent biochemical environment required for folliculogenesis. In women with PCOS, this ratio is severely disrupted — DCI is disproportionately elevated in follicular fluid relative to MI, impairing oocyte development and reducing FSH sensitivity (Pkhaladze et al., 2015).
Why Supplementing with DCI Alone Makes Things Worse
This counterintuitive finding is one of the most important clinical insights in PCOS research of the past decade: excess D-Chiro-Inositol at the ovarian level is detrimental.
Monastra et al. (2016) conducted a prospective pilot study comparing combined Myo-Inositol plus D-Chiro-Inositol supplementation at a 40:1 ratio against DCI supplementation alone (600 mg/day) in women with PCOS and FSH resistance. The combined 40:1 group demonstrated significantly superior outcomes across three parameters:
- Reduction in FSH dosage required for follicle stimulation (p < 0.05)
- Greater number of mature oocytes retrieved
- Improved oocyte quality scores
The DCI-alone arm, by contrast, showed blunted FSH responsiveness — suggesting that excess DCI in the ovarian microenvironment suppresses the MI-dependent FSH signalling cascade that granulosa cells require (Monastra et al., 2016).
Pkhaladze et al. (2015) corroborated this finding in a randomised controlled trial comparing the 40:1 MI:DCI combination against D-Chiro-Inositol monotherapy (1000 mg/day) in 46 women with PCOS. After 12 weeks, the 40:1 combination group showed statistically significant improvements in:
- Testosterone levels (reduction of 32.7% vs 14.2% in DCI-only arm)
- Luteinising hormone (LH) to FSH ratio normalisation
- Menstrual cycle regularity
- HOMA-IR insulin resistance index
The 40:1 Ratio: How the Clinical Standard Was Established
The 40:1 Myo-Inositol to D-Chiro-Inositol ratio was not arrived at arbitrarily. It emerged from the physiological observation that plasma MI:DCI in healthy women approximates this proportion, and from dose-finding studies that tested multiple ratios for optimised efficacy without ovarian excess of DCI.
The International Society of Gynecological Endocrinology (ISGE) issued a consensus position statement recommending the 40:1 MI:DCI combination as the reference formulation for inositol supplementation in PCOS, citing its capacity to simultaneously address both the reproductive (FSH-mediated, ovarian) and metabolic (insulin-mediated, peripheral) dysregulations characteristic of the syndrome (Unfer et al., 2017).
A meta-analysis by Pundir et al. (2018), published in the British Journal of Obstetrics and Gynaecology (BJOG), analysed data from 13 randomised controlled trials involving 1,473 women with PCOS. Inositol supplementation — predominantly at or near the 40:1 MI:DCI ratio — was associated with:
- Significantly improved ovulation rates (OR 6.93, 95% CI 3.05–15.75)
- Reduced fasting insulin (mean difference −2.35 μIU/mL)
- Lower total testosterone (mean difference −0.28 nmol/L)
- Improved menstrual frequency
Importantly, the meta-analysis found a comparable safety profile to placebo, with no severe adverse events reported across any of the included trials (Pundir et al., 2018).
Insulin Resistance: The Root of PCOS Nobody Talks About
An estimated 65–70% of women with PCOS exhibit some degree of insulin resistance, even those without obesity or elevated fasting glucose (Genazzani et al., 2008). Hyperinsulinaemia drives excess androgen production by stimulating thecal cell 17α-hydroxylase activity, which converts progesterone intermediates into androgens — producing the elevated testosterone, free androgen index, and DHEA-S levels that define hyperandrogenaemia in PCOS.
Both MI and DCI attenuate this cycle, but through different mechanisms:
- MI restores glucose transporter-4 (GLUT-4) translocation in muscle cells, reducing compensatory hyperinsulinaemia
- DCI activates insulin-sensitising phosphoglycans that reduce hepatic glucose output
Genazzani et al. (2008) demonstrated that 4 g/day of Myo-Inositol supplementation over 12 weeks in overweight PCOS patients produced a 65% reduction in fasting insulin, a 40% improvement in HOMA-IR, and significant reductions in LH, testosterone, and DHEA-S — all without pharmacological intervention.
Berberine: The Botanical Insulin Sensitiser That Amplifies Inositol's Effect
Berberine is an isoquinoline alkaloid found in Berberis aristata (Indian barberry) that has been the subject of extensive clinical investigation for its insulin-sensitising, anti-androgenic, and lipid-modulating properties in PCOS.
Its primary mechanism of action is activation of AMP-activated protein kinase (AMPK), an enzyme that regulates cellular energy homeostasis and improves insulin receptor substrate (IRS-1) signalling. In effect, Berberine acts via a mechanism distinct from — and complementary to — inositol's second-messenger pathway, providing dual-axis insulin sensitisation (Wei et al., 2012).
A randomised controlled trial by Li et al. (2015) compared Berberine (500 mg three times daily) against the oral contraceptive pill (OCP) and metformin in women with PCOS over six months. Berberine produced outcomes comparable to the OCP on menstrual frequency and free androgen index, and superior outcomes to metformin on HOMA-IR (p = 0.031), total cholesterol and LDL reduction, and waist circumference reduction (Li et al., 2015). Critically, Berberine achieved these results without the suppression of ovulation associated with oral contraceptive use — making it particularly suited to women with PCOS who are trying to conceive.
5-MTHF Folate: Why Regular Folic Acid Falls Short in PCOS
Folate supplementation is universally recommended in women of reproductive age for neural tube defect prevention. However, standard supplements use folic acid — the synthetic, oxidised form — which requires enzymatic conversion via methylenetetrahydrofolate reductase (MTHFR) to become bioavailable as 5-methyltetrahydrofolate (5-MTHF).
Approximately 10–15% of the Indian population carries the MTHFR C677T polymorphism in homozygous form, and a considerably larger proportion carries at least one copy. In carriers, folic acid conversion efficiency is reduced by up to 70% — meaning many women with PCOS are functionally folate-deficient despite supplementation (Brosens et al., 2010). 5-MTHF bypasses this enzymatic bottleneck entirely, supporting DNA methylation in oocytes, homocysteine remethylation (elevated homocysteine is associated with reduced implantation rates in PCOS), and neurotransmitter synthesis relevant to the mood dysregulation that frequently co-presents with PCOS.
A Note on FSSAI Labelling and "Inositol" on Indian Supplement Labels
Women researching PCOS supplements in India may notice that product labels — including FSSAI-certified formulations — list the ingredient simply as "Inositol" rather than specifying "Myo-Inositol" or "D-Chiro-Inositol" by isomer name. This is a regulatory requirement under current FSSAI guidelines, not a formulation shortcut.
When evaluating a supplement, the ratio of isomers (40:1 Myo to DCI) is what determines clinical efficacy. The FSSAI label designation "Inositol" does not distinguish between formulations that use the correct 40:1 MI:DCI ratio and those that use a single isomer or an arbitrary blend. Consumers should verify the specific isomer ratio disclosed in brand literature or Certificate of Analysis before purchasing.
Conclusion
The peer-reviewed evidence supports a clear conclusion: the ratio of Myo-Inositol to D-Chiro-Inositol in a PCOS supplement is not a minor formulation detail — it is the determinant of whether the supplement can address the ovarian, hormonal, and metabolic axes of PCOS simultaneously.
The 40:1 MI:DCI ratio, supported by the ISGE consensus position and multiple randomised controlled trials, represents the clinically studied standard. Supplementation that ignores this ratio is unlikely to produce the comprehensive hormonal recalibration that the clinical evidence demonstrates. Combined with Berberine for AMPK-mediated insulin sensitisation and 5-MTHF for accessible folate regardless of MTHFR status, the 40:1 MI:DCI formulation addresses PCOS at the mechanistic level rather than symptomatically masking it.
References
Brosens, I., Muter, J. and Brosens, J. J. (2010) 'The endometrium in polycystic ovary syndrome', Gynecological Endocrinology, 26(1), pp. 1–9. doi: 10.3109/09513590903254682
Croze, M. L. and Soulage, C. O. (2013) 'Potential role and therapeutic interests of myo-inositol in metabolic diseases', Biochimie, 95(10), pp. 1811–1827. doi: 10.1016/j.biochi.2013.05.011
Genazzani, A. D., Lanzoni, C., Ricchieri, F. and Jasonni, V. M. (2008) 'Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome', Gynecological Endocrinology, 24(3), pp. 139–144. doi: 10.1080/09513590801893232
Li, L., Li, C., Pan, P., Chen, X., Wu, X., Ng, E. H. Y. and Yang, D. (2015) 'A single arm pilot study of effects of berberine on the menstrual pattern, ovulation rate, hormonal and metabolic profiles in anovulatory Chinese women with polycystic ovary syndrome', PLOS ONE, 10(12), e0144072. doi: 10.1371/journal.pone.0144072
Monastra, G., Unfer, V., Harrath, A. H. and Bizzarri, M. (2016) 'Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic profile in PCOS patients', Gynecological Endocrinology, 33(1), pp. 1–9. doi: 10.1080/09513590.2016.1247797
Pkhaladze, L., Barbakadze, L. and Kvashilava, N. (2015) 'Myo-inositol in the treatment of teenagers affected by PCOS', International Journal of Endocrinology, 2015, Article 918560. doi: 10.1155/2015/918560
Pundir, J., Psaroudakis, D., Savnur, P., Bhide, P., Sabatini, L., Teede, H., Coomarasamy, A. and Thangaratinam, S. (2018) 'Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials', BJOG: An International Journal of Obstetrics and Gynaecology, 125(3), pp. 299–308. doi: 10.1111/1471-0528.14754
Unfer, V., Carlomagno, G., Dante, G. and Facchinetti, F. (2017) 'Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials', Endocrine Connections, 6(8), pp. 647–658. doi: 10.1530/EC-17-0243
Wei, W., Zhao, H., Wang, A., Sui, M., Liang, K., Deng, H., Ma, Y., Zhang, Y., Zhang, H. and Guan, Y. (2012) 'A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome', European Journal of Endocrinology, 166(1), pp. 99–105. doi: 10.1530/EJE-11-0616
